Type Whole antibody Target CCR4 Routes of
administration Intravenous | Source Humanized (from mouse) Trade names Poteligeo ATC code L01XC25 (WHO) | |
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd. It has also been licensed to Amgen for development as a therapy for Asthma.
In 2016 it was in phase 1 clinical trials in combination with utomilumab (PF-05082566) for solid cancers.
References
Mogamulizumab Wikipedia(Text) CC BY-SA